Mylan releases generic version of Trilafon
CANONSBURG – Mylan N.V. announced Thursday the U.S. launch of Perphenazine Tablets USP, in 2-, 4-, 8- and 16- mg doses, a generic version of the reference listed drug, Trilafon tablets, originally marketed by Schering. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.
Perphenazine tablets had U.S. sales of approximately $41 million for the 12 months ending Feb. 28, according to IMS Health.